Steven M Jones

Summary

Affiliation: Public Health Agency of Canada
Country: Canada

Publications

  1. pmc Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, USA
    J Virol 82:5664-8. 2008
  2. ncbi request reprint Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S404-12. 2007
  3. pmc Effective post-exposure treatment of Ebola infection
    Heinz Feldmann
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Pathog 3:e2. 2007
  4. pmc The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola
    Allen Grolla
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Negl Trop Dis 5:e1183. 2011
  5. pmc Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Negl Trop Dis 6:e1575. 2012
  6. doi request reprint Immune Response to Marburg Virus Angola Infection in Nonhuman Primates
    Lisa Fernando
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
    J Infect Dis 212:S234-41. 2015
  7. ncbi request reprint Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada
    Nat Med 11:786-90. 2005
  8. pmc Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5547. 2009
  9. pmc Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus
    Darryl Falzarano
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
    J Infect Dis 204:S1082-9. 2011
  10. doi request reprint Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    Clin Immunol 141:218-27. 2011

Collaborators

Detail Information

Publications22

  1. pmc Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, USA
    J Virol 82:5664-8. 2008
    ..This is the first demonstration of complete postexposure protection against an Ebola virus in nonhuman primates and provides further evidence that postexposure vaccination may have utility in treating exposures to filoviruses...
  2. ncbi request reprint Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
    J Infect Dis 196:S404-12. 2007
    ..In the present study, we used the mouse model for Ebola hemorrhagic fever to assess the safety and efficacy of a vaccine based on a live attenuated vesicular stomatitis virus expressing the Zaire ebolavirus (ZEBOV) glycoprotein...
  3. pmc Effective post-exposure treatment of Ebola infection
    Heinz Feldmann
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Pathog 3:e2. 2007
    ....
  4. pmc The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola
    Allen Grolla
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Negl Trop Dis 5:e1183. 2011
    ..Marburg virus (MARV), a zoonotic pathogen causing severe hemorrhagic fever in man, has emerged in Angola resulting in the largest outbreak of Marburg hemorrhagic fever (MHF) with the highest case fatality rate to date...
  5. pmc Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Negl Trop Dis 6:e1575. 2012
    ..These results indicate that MAbs particularly when used as an oligoclonal set are a potential therapeutic for post-exposure treatment of EBOV infection...
  6. doi request reprint Immune Response to Marburg Virus Angola Infection in Nonhuman Primates
    Lisa Fernando
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada
    J Infect Dis 212:S234-41. 2015
    ..However, very little is known about the pathogenicity of MARV Angola, as few studies have been conducted to date. Therefore, the immune response was examined in MARV Angola-infected nonhuman primates...
  7. ncbi request reprint Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
    Steven M Jones
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada
    Nat Med 11:786-90. 2005
    ..No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model...
  8. pmc Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5547. 2009
    ..Zaire ebolavirus (ZEBOV) produces a lethal viral hemorrhagic fever in humans and non-human primates...
  9. pmc Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus
    Darryl Falzarano
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
    J Infect Dis 204:S1082-9. 2011
    ....
  10. doi request reprint Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    Clin Immunol 141:218-27. 2011
    ..All 8 MAb improved survival rates by 33%-100% against a high dose lethal challenge with mouse-adapted ZEBOV. This work has important implications for further development of vaccines and immunotherapies for ZEBOV infection...
  11. ncbi request reprint In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein
    Hideki Ebihara
    Department of Special Pathogens, International Research Center for Infectious Diseases, University of Tokyo, Tokyo, Japan
    J Infect Dis 196:S313-22. 2007
    ..These findings demonstrate that the incorporation of a foreign gene will attenuate ZEBOV in vivo but that these viruses still have potential for in vitro and in vivo research applications...
  12. ncbi request reprint Ebola virus ecology: a continuing mystery
    Heinz Feldmann
    Special Pathogens Program, National Microbiology Laboratory, Health Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Trends Microbiol 12:433-7. 2004
  13. pmc Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model
    Dennis A Bente
    Special Pathogens Program, National Microbiology Laboratory, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada
    J Virol 84:11089-100. 2010
    ..This new mouse model exhibits key features of fatal human CCHF, proves useful for the testing of therapeutic strategies, and can be used to study virus attenuation...
  14. ncbi request reprint Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus
    Darwyn Kobasa
    Respiratory Viruses, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Nature 445:319-23. 2007
    ..The ability of influenza viruses to modulate host immune responses, such as that demonstrated for the avian H5N1 influenza viruses, may be a feature shared by the virulent influenza viruses...
  15. ncbi request reprint Therapy and prophylaxis of Ebola virus infections
    Heinz Feldmann
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
    Curr Opin Investig Drugs 6:823-30. 2005
    ..This review will summarize and discuss the current therapeutic and prophylactic strategies for Ebola hemorrhagic fever...
  16. ncbi request reprint Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha
    Ute Stroher
    National Microbiology Laboratory, Health Canada, and Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    J Infect Dis 189:1164-7. 2004
    ..In conclusion, ribavirin alone is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infections. Clinical trials with IFN- alpha might be justified to determine a beneficial effect on the outcome of SARS...
  17. ncbi request reprint Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens
    Soraya Shahhosseini
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
    J Virol Methods 143:29-37. 2007
    ..The anti-GP MAbs with different epitope specificities as an oligoclonal cocktail could be tested for therapy...
  18. ncbi request reprint Differential expression of the Ebola virus GP(1,2) protein and its fragments in E. coli
    Dipankar Das
    University of Alberta, Edmonton, Alta, Canada T6G 2N8
    Protein Expr Purif 54:117-25. 2007
    ....
  19. pmc Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine
    Kathleen M Daddario-DiCaprio
    Virology Division, USAMRIID, Fort Detrick, MD 21702 5011, USA
    J Virol 80:9659-66. 2006
    ..These data suggest that the VSVDeltaG/MARVGP-Musoke vaccine should be sufficient to protect against all known MARV strains...
  20. ncbi request reprint Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment
    Kathleen M Daddario-DiCaprio
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    Lancet 367:1399-404. 2006
    ..We aimed to test the efficacy of a replication-competent vaccine based on attenuated recombinant vesicular stomatitis virus (rVSV), as a postexposure treatment for MARV haemorrhagic fever...
  21. ncbi request reprint Ebola and Marburg viruses: pathogenesis and development of countermeasures
    Lisa E Hensley
    Virology Division, U S Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
    Curr Mol Med 5:761-72. 2005
    ..In addition, substantial progress has been made in developing recombinant vaccines against these viruses...
  22. ncbi request reprint Evolutionary and biomedical insights from the rhesus macaque genome
    Richard A Gibbs
    Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA
    Science 316:222-34. 2007
    ..The complete description of the macaque genome blueprint enhances the utility of this animal model for biomedical research and improves our understanding of the basic biology of the species...